Cervical cancer vaccine in India: Cost, doses, name, age limit - All details
"The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it. The Department of Biotechnology has taken a lead in the matter and are in collaborative mode," he said.
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400.
Union Minister of Science and Technology Jitendra Singh on Thursday attended an event held to announce the scientific completion of the vaccine.
Scientific completion implies that R&D activities pertaining to the vaccine are complete and now the next step of making them available to the public would take place.
Speaking at the event, Singh said Covid has raised awareness about preventive healthcare leading to the development of vaccines like the one against cervical cancer.
"The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it. The Department of Biotechnology has taken a lead in the matter and are in collaborative mode," he said.
"Scientific efforts at times do not get the scale of recognition they deserve. So this event is to celebrate that scientific completion," he said.
CEO of the Serum Institute of India (SII) Adar Poonawalla, who was also present, told reporters on the sidelines of the event, "The cervical cancer vaccine will be affordable and would be available in the range of Rs 200-400. However, the final price is yet to be decided".
Poonawalla said the vaccine will be possibly launched by the end of the year.
First the vaccine would be made available through the government channel and from next year onwards some private partners would be involved too, he said.
Poonawalla also said that a plan to make 200 million doses is in place and first the vaccine would be given in India and only after that it will be exported to other countries.
Rajesh Gokhale, Department of Biotechnology Secretary, said over 2000 volunteers participated across the country for this vaccine.
"Partnerships between private-public are becoming very important in such research, this co-creation is what is going to make all the difference in the world," he said.
Dr N Kalaiselvi, Director General, CSIR said this is the first stepping stone and research in the field and it will further continue.
"This government has taken the most amount of care to come up with this type of innovation, making us 'atmanirbhar'," she said.
According to the officials, the qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
The Drugs Controller General of India (DCGI) had in July granted market authorisation to the SII to manufacture the vaccine against cervical cancer.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
EPFO Pension Schemes: Early pension, retirement pension, nominee pension and 4 other pension schemes that every private sector employee should know
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
01:26 PM IST